Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 116

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 1
Chunk 116
---
 issuance of common stock, net of underwriting discounts— 151,340 Payment of issuance costs— (259)Proceeds from exercise of stock options4 5,721 Net cash provided by financing activities4 156,802 NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH160,610 111,296 Cash, cash equivalents and restricted cash at beginning of period561,380 332,359 Cash, cash equivalents and restricted cash at end of period$721,990 $443,655 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Property and equipment purchases in accounts payable and accrued expenses$15 $230 

The following table provides a reconciliation of the ending cash, cash equivalents and restricted cash as of each of the periods shown above:

MARCH 31,20252024Cash and cash equivalents$720,541 $442,443 Restricted cash1,449 1,212 Total cash, cash equivalents and restricted cash$721,990 $443,655 

See notes to condensed consolidated financial statements.

8

KEROS THERAPEUTICS, INC. 

Notes to Condensed Consolidated Financial Statements 

(Unaudited)

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION 

Keros Therapeutics, Inc. (“Keros” or the “Company”) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins. One of the Company’s product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension (“PAH”) and for the treatment of cardiovascular disorders. The Company's second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. The Company’s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (“cytopenias”), including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (“MDS”) and in patients with myelofibrosis.Since its inception in 2015, the Company has devoted the majority of its resources to business planning